Integer Holdings ( (ITGR) ) just unveiled an announcement.
Integer Holdings Corporation reported a strong start to 2025, with first-quarter sales increasing by 7% to $437 million and a 14% rise in adjusted operating income. Despite a GAAP loss due to debt conversion expenses, the company saw significant growth in its cardio and vascular segment and adjusted net income. Integer completed a $1.0 billion convertible notes offering, which is expected to reduce interest expenses and support future growth, including acquisitions of Precision Coating and VSi Parylene. The company raised its adjusted EPS outlook, reflecting confidence in continued sales and income growth.
Spark’s Take on ITGR Stock
According to Spark, TipRanks’ AI Analyst, ITGR is a Outperform.
Integer Holdings presents a strong financial performance with robust revenue growth and cash flow management, supported by a positive earnings outlook and strategic acquisitions. However, technical indicators suggest weak market momentum, and the high P/E ratio implies the stock is overvalued. The overall score reflects these strengths and weaknesses, positioning Integer as a stable but currently expensive investment in the Medical Devices industry.
To see Spark’s full report on ITGR stock, click here.
More about Integer Holdings
Integer Holdings Corporation operates in the medical device industry, focusing on the development and manufacturing of innovative medical technologies. The company is known for its cardio and vascular products, cardiac rhythm management, and neuromodulation solutions, targeting growth markets through product launches and strategic acquisitions.
YTD Price Performance: -8.82%
Average Trading Volume: 557,709
Technical Sentiment Signal: Sell
Current Market Cap: $4.12B
See more data about ITGR stock on TipRanks’ Stock Analysis page.